Skip to main content

Acute posterior multifocal placoid pigment epitheliopathy after alemtuzumab treatment for relapsing–remitting multiple sclerosis

Journal of Neurology volume 266, pages 1539–1540 (2019)Cite this article

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Fig. 1

References

  1. Hill-Cawthorne GA, Button T, Tuohy O et al (2012) Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry 83:298–304. https://doi.org/10.1136/jnnp-2011-300826

    Article  PubMed  Google Scholar 

  2. Gass JD (1968) Acute posterior multifocal placoid pigment epitheliopathy. Arch Ophthalmol 80:177–185

    Article  CAS  PubMed  Google Scholar 

  3. Burke TR, Chu CJ, Salvatore S et al (2017) Application of OCT-angiography to characterise the evolution of chorioretinal lesions in acute posterior multifocal placoid pigment epitheliopathy. Eye Lond Engl 31:1399–1408. https://doi.org/10.1038/eye.2017.180

    Article  CAS  Google Scholar 

  4. Algahtani H, Alkhotani A, Shirah B (2016) Neurological manifestations of acute posterior multifocal placoid pigment epitheliopathy. J Clin Neurol Seoul Korea 12:460. https://doi.org/10.3988/jcn.2016.12.4.460

    Article  Google Scholar 

  5. Guarnera C, Bramanti P, Mazzon E (2017) Alemtuzumab: a review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis. Ther Clin Risk Manag 13:871–879. https://doi.org/10.2147/TCRM.S134398

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

JJ and AC are supported by the National Institute of Health Research Cambridge Centre for Biomedical Research. The patient was on a trial of alemtuzumab, CAMMS 32400507, funded by Sanofi.

Author information

Authors and Affiliations

  1. School of Clinical Medicine, University of Cambridge, Cambridge, UK

    Jiali Gao

  2. Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK

    Joanne Jones & Alasdair Coles

  3. Department of Ophthalmology, Addenbrooke’s Hospital, University of Cambridge, Cambridge, UK

    Erika M. Damato

Authors
  1. Jiali Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joanne Jones
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Erika M. Damato
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alasdair Coles
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jiali Gao.

Ethics declarations

Conflicts of interest

Alasdair Coles received honoraria and travel expenses from Genzyme (Sanofi), up until 2017.

Ethical approval

The patient provided informed written consent in accordance with the ethics standards laid down in the 1964 Declaration of Helsinki and its later amendments.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Gao, J., Jones, J., Damato, E.M. et al. Acute posterior multifocal placoid pigment epitheliopathy after alemtuzumab treatment for relapsing–remitting multiple sclerosis. J Neurol 266, 1539–1540 (2019). https://doi.org/10.1007/s00415-019-09288-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-019-09288-y

Keywords

  • Alemtuzumab
  • Multiple sclerosis
  • APMPPE—acute posterior multifocal placoid pigment epitheliopathy
  • Autoimmunity